The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1210
June 6, 2005
View Complete Issue         Table of Contents 2019 
Entecavir (Baraclude) for Chronic Hepatitis B
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Entecavir (Baraclude) for Chronic Hepatitis B
June 6, 2005 (Issue: 1210)
Entecavir (Baraclude - Bristol-Myers Squibb), a nucleoside analog, has been approved by the FDA for treatment of adults with active chronic hepatitis B virus (HBV) infection.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Entecavir (Baraclude) for Chronic Hepatitis B
Article code: 1210c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.